SG10201900892SA - Composition containing apomorphine and a divalent metal cation - Google Patents

Composition containing apomorphine and a divalent metal cation

Info

Publication number
SG10201900892SA
SG10201900892SA SG10201900892SA SG10201900892SA SG10201900892SA SG 10201900892S A SG10201900892S A SG 10201900892SA SG 10201900892S A SG10201900892S A SG 10201900892SA SG 10201900892S A SG10201900892S A SG 10201900892SA SG 10201900892S A SG10201900892S A SG 10201900892SA
Authority
SG
Singapore
Prior art keywords
metal cation
divalent metal
composition containing
composition
apomorphine
Prior art date
Application number
SG10201900892SA
Other languages
English (en)
Inventor
Ian Philip Leader
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51265458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201900892S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of SG10201900892SA publication Critical patent/SG10201900892SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10201900892SA 2014-08-01 2015-07-31 Composition containing apomorphine and a divalent metal cation SG10201900892SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14002689.9A EP2979688A1 (fr) 2014-08-01 2014-08-01 Composition contenant de l'apomorphine et un cation de métal divalent

Publications (1)

Publication Number Publication Date
SG10201900892SA true SG10201900892SA (en) 2019-02-27

Family

ID=51265458

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700098YA SG11201700098YA (en) 2014-08-01 2015-07-31 Composition containing apomorphine and a divalent metal cation
SG10201900892SA SG10201900892SA (en) 2014-08-01 2015-07-31 Composition containing apomorphine and a divalent metal cation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700098YA SG11201700098YA (en) 2014-08-01 2015-07-31 Composition containing apomorphine and a divalent metal cation

Country Status (14)

Country Link
US (1) US11419863B2 (fr)
EP (2) EP2979688A1 (fr)
JP (1) JP6760923B2 (fr)
KR (1) KR102485809B1 (fr)
AR (1) AR101389A1 (fr)
AU (1) AU2015295817C1 (fr)
CA (1) CA2954223C (fr)
DK (1) DK3174526T4 (fr)
ES (1) ES2757060T5 (fr)
FI (1) FI3174526T4 (fr)
MY (1) MY180540A (fr)
SG (2) SG11201700098YA (fr)
TW (1) TW201605448A (fr)
WO (1) WO2016015875A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
WO2009064928A1 (fr) * 2007-11-13 2009-05-22 Cadence Pharmaceuticals Acétaminophène par voie intraveineuse en dose réduite
DK2952191T3 (en) 2009-06-12 2018-12-10 Sunovion Pharmaceuticals Inc Sublingual apomorphine
WO2011028799A2 (fr) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Formulations transmuqueuses de gangliosides
US20110111101A1 (en) 2009-11-06 2011-05-12 Graham Packaging Company, L.P. Method and apparatus of packaging beverage mixture
EP2545905A1 (fr) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
HUE042425T2 (hu) * 2012-06-05 2019-06-28 Neuroderm Ltd Apomorfint és szerves savakat tartalmazó készítmények és alkalmazásaik
CA2999675C (fr) 2015-09-28 2023-10-17 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanee

Also Published As

Publication number Publication date
FI3174526T4 (fi) 2023-08-31
JP6760923B2 (ja) 2020-09-23
AU2015295817A1 (en) 2017-02-16
KR20170068435A (ko) 2017-06-19
SG11201700098YA (en) 2017-02-27
EP3174526B1 (fr) 2019-09-11
ES2757060T3 (es) 2020-04-28
KR102485809B1 (ko) 2023-01-05
CA2954223C (fr) 2022-05-10
AU2015295817B2 (en) 2020-04-02
WO2016015875A1 (fr) 2016-02-04
MY180540A (en) 2020-12-01
US20170136002A1 (en) 2017-05-18
AU2015295817C1 (en) 2022-11-17
US11419863B2 (en) 2022-08-23
DK3174526T4 (da) 2023-04-24
EP3174526A1 (fr) 2017-06-07
DK3174526T3 (da) 2019-10-07
JP2017522358A (ja) 2017-08-10
TW201605448A (zh) 2016-02-16
EP2979688A1 (fr) 2016-02-03
EP3174526B2 (fr) 2023-03-22
AR101389A1 (es) 2016-12-14
ES2757060T5 (es) 2023-08-21
CA2954223A1 (fr) 2016-02-04

Similar Documents

Publication Publication Date Title
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2017001379A (es) Producto antiseptico, proceso para prepararlo y su uso.
PH12016501807A1 (en) Novel compounds
WO2019040106A3 (fr) Composés, sels associés et méthodes pour le traitement de maladies
MX2018016290A (es) Agente antidesgaste.
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MD4780C1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
GEP20186893B (en) Pyrazines modulators of gpr6
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
MX2018002075A (es) Composicion que comprende taninos.
SG10201900892SA (en) Composition containing apomorphine and a divalent metal cation
TN2015000524A1 (en) Pharmaceutical compositions
WO2019040104A3 (fr) Composés, sels associés et méthodes de traitement de maladies
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
PH12017500149A1 (en) Hair products containing polyetheramine